Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease

NCT ID: NCT02863757

Last Updated: 2025-03-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

1500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-08-01

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the disease progression in CHB/NAFLD compared with CHB and NAFLD including liver cirrhosis, cirrhotic complications and hepatocellular carcinoma (HCC).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Hepatitis B Nonalcoholic Fatty Liver Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CHB Group

Patients with chronic hepatitis B

No interventions assigned to this group

CHB/NAFLD Group

Patients with chronic hepatitis B and comorbid nonalcoholic fatty liver disease

No interventions assigned to this group

NAFLD Group

Patients with nonalcoholic fatty liver disease

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Liver biopsy proved CHB and/or NAFLD at baseline;
* Chinese
* Follow-up duration\>12 months

Exclusion Criteria

* Other liver diseases;
* Secondary causes of hepatic steatosis;
* Alcohol abuse;
* Liver cirrhosis, cirrhosis related complications or HCC at baseline;
* Malignancy;
* History of liver transplantation
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Humanity and Health Research Centre

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Humanity and Health GI and Liver Centre

Hong Kong, Hong Kong, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

George Lau, MD

Role: CONTACT

+852 2861 3777

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

George KK Lau, MD

Role: primary

(852)28613777

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H&H_NAFLD/CHB

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.